Cargando…

P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas

Molecular characterization of gliomas has uncovered genomic signatures with significant impact on tumor diagnosis and prognostication. CDKN2A is a tumor suppressor gene involved in cell cycle control. Homozygous deletion of the CDKN2A/B locus has been implicated in both gliomagenesis and tumor progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vij, Meenakshi, Cho, Benjamin B., Yokoda, Raquel T., Rashidipour, Omid, Umphlett, Melissa, Richardson, Timothy E., Tsankova, Nadejda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155323/ https://www.ncbi.nlm.nih.gov/pubmed/37138345 http://dx.doi.org/10.1186/s40478-023-01573-2

Ejemplares similares

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

SDPS-27 P16 IMMUNOHISTOCHEMISTRY AS A SCREENING TOOL FOR HOMOZYGOUS CDKN2A DELETIONS IN GLIAL TUMORS
por: Zschernack, Valentina, et al.
Publicado: (2023)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
por: Huang, L. Eric
Publicado: (2022)

Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas
por: Tang, Vivian, et al.
Publicado: (2023)

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
por: Sievers, Philipp, et al.
Publicado: (2020)

CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review
por: Yuile, Alexander, et al.
Publicado: (2023)

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances
por: Geyer, Lucas, et al.
Publicado: (2023)

Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma
por: Cottone, Lucia, et al.
Publicado: (2020)

DIPG-33. P16 IMMUNOHISTOCHEMICAL EXPRESSION AS A SURROGATE ASSESSMENT OF CDKN2A ALTERATION IN GLIOMAS LEADING TO PROGNOSTIC SIGNIFICANCES
por: Geyer, Lucas, et al.
Publicado: (2023)

Frequent homozygous deletion of Cdkn2a/2b in tremolite‐induced malignant mesothelioma in rats
por: Okazaki, Yasumasa, et al.
Publicado: (2020)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report
por: Umphlett, Melissa, et al.
Publicado: (2020)

Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy
por: Grard, Marion, et al.
Publicado: (2021)

HGG-08. COMBINATORIAL ACTIVITY OF CDK4/6-INHIBITORS AND TRAMETINIB IN PEDIATRIC HIGH-GRADE GLIOMA WITH BRAFV600E MUTATION AND HOMOZYGOUS CDKN2A DELETION
por: Mayr, Lisa, et al.
Publicado: (2023)

Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas
por: Kocakavuk, Emre, et al.
Publicado: (2023)

An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion
por: Cheaney, Barry, et al.
Publicado: (2019)

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas
por: Marker, Daniel F., et al.
Publicado: (2020)

Co‐occurrence of CDKN2A/B and IFN‐I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma
por: Peng, Yuan, et al.
Publicado: (2022)

A human laterality disorder associated with a homozygous WDR16 deletion
por: Ta-Shma, Asaf, et al.
Publicado: (2015)

FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
por: Chung, Catherine T-S, et al.
Publicado: (2010)

Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1.
por: Maelandsmo, G. M., et al.
Publicado: (1995)

CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A
por: Tu, Q, et al.
Publicado: (2018)

High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene
por: Carén, Helena, et al.
Publicado: (2008)

Chromosomal instability in adult-type diffuse gliomas
por: Richardson, Timothy E., et al.
Publicado: (2022)

Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis
por: Ortiz, Berenice, et al.
Publicado: (2014)

Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival
por: Barresi, Valeria, et al.
Publicado: (2021)

Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study
por: Park, Yae Won, et al.
Publicado: (2023)

Germline hemizygous deletion of CDKN2A–CDKN2B locus in a patient presenting with Li–Fraumeni syndrome
por: Chan, Sock Hoai, et al.
Publicado: (2016)

U-Net Based Segmentation and Characterization of Gliomas
por: Kihira, Shingo, et al.
Publicado: (2022)

Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques
por: Chopra, Anita, et al.
Publicado: (2016)

Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign
por: Kihira, Shingo, et al.
Publicado: (2023)

Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma
por: Wang, Haiwei, et al.
Publicado: (2021)

CDKN2A Deletion Leading to Hematogenous Metastasis of Human Gastric Carcinoma
por: Qiao, Juanli, et al.
Publicado: (2021)

Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma
por: Vrugt, Bart, et al.
Publicado: (2023)

MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting
por: Sakai, Yu, et al.
Publicado: (2020)

Subtyping of gliomas of various WHO grades by the application of immunohistochemistry
por: Popova, Svetlana N, et al.
Publicado: (2014)

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
por: Li, Junjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sfprve0fs348cbfk847htp7qjp